Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.
You may also be interested in...
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.
Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis
Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.